Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Meta Materials Stock Is a Speculative Play That Could Pay Off Big

By Chris Lau, InvestorPlace Contributor

Speculators are betting that Meta has promising nanocomposites that address multiple markets, realizing revenue in 1H/2022.

Why Investors Should Bet on Corsair For PC Gaming

By Chris Lau, InvestorPlace Contributor

Corsair deserves a higher premium but for now, markets fail to recognize the strength of CRSR stock in the high-end gaming market.

Why Investing in VXRT Stock is a Coin Flip

By Chris Lau, InvestorPlace Contributor

Vaxart is a gamble for biotechnology investors, with its upside too dependent on the approval of an oral vaccine.

7 Tech Stocks That are Down Too Far to Overlook Now

By Chris Lau, InvestorPlace Contributor

Few tech stocks are on sale as the sector reaches all-time highs, but these shares recently disappointed investors and are now a bargain.

Investors Should Not Sell Palantir Stock

By Chris Lau, InvestorPlace Contributor

PLTR stock is attractive because of its cool platforms that appeal to the military, healthcare, and connected car sectors.

Load More